09/29/2015 - 3:46pm

Avalere Health’s Mike Johnsrud moderated a panel of leading stakeholders in the specialty pharmacy arena at an exclusive National Community Pharmacists Association day-long forum that explored specialty pharmacy as a viable and promising business model for entrepreneurial independent pharmacists. DSNTV was on hand to capture the highlights of that panel in this video, including insights from Diplomat Pharmacy’s Ela Lourido and H.D. Smith Specialty Solutions’ Tom Doyle.

09/25/2015 - 11:04am

Health benefit plan cost trend rates for 2016 will increase for most medical plan options and increase substantially for prescription drug coverage to double-digit rates, according to forecasts compiled in the 2016 Segal Health Plan Cost Trend Survey, Segal’s nineteenth annual survey of health plan cost trends. Trend is the forecast of annual gross per capita claims cost increases.

09/24/2015 - 11:00am

CVS Health has committed $10 million to SU2C over three years, supported by an annual in-store campaign. 

09/23/2015 - 5:21pm

This summer independent pharmacists traveled from around the nation to the Washington, D.C., area for an exclusive National Community Pharmacists Association forum on the promise of specialty pharmacy. Drug Store News captured the highlights of that day that not only confirmed that community pharmacy can play a crucial role in the delivery of specialty medicines, but also provided a road map for independents interested in a specialty practice.

09/23/2015 - 12:12pm

The Food and Drug Administration on Wednesday announced the approval of Taiho Oncology’s Lonsurf (trifluridine and tipiracil).

09/22/2015 - 10:13am

Keveyis was recently approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. 

09/16/2015 - 3:24pm

Care Advantage provides more than 70 therapies and is currently authorized to distribute in all 50 states, districts and territories in the U.S.

09/11/2015 - 3:27pm

Mission Pharmacal announced Friday that it would be relaunching its Lithostat (acetohydroxamic acid) kidney stones treatment.

09/11/2015 - 12:05pm

Repatha is one in a new class of cholesterol medications called PSCK9 (proprotein convertase substilisin kexin type 9) inhibitors, which are potentially an alternative to statins.